Proteomics International Laboratories Ltd stock (April 2026)

Proteomics Internati...

ASX:PIQ

$ 0,28

+ $0,03 (12,00%)

0,28 $

+$0,03 (12,00%)

End-of-day quote: 04/17/2026

Proteomics International Laboratories Ltd Stock Value

The current analyst rating for ASX:PIQ is Underperform.

Underperform

Proteomics International Laboratories Ltd Company Info

EPS Growth 3Y

0,00%

Market Cap

$0,05 B

Long-Term Debt

$0,00 B

Quarterly earnings

05/25/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2001

Industry

Health Care

Country

Australia

Website

Proteomics International Laboratories Ltd

ISIN Number

AU000000PIQ0

Website

http://www.proteomics.com.au

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,43

53.57%

Last Update: 04/20/2026

Analysts: 1

Highest Price Target $0,43

Average Price Target $0,43

Lowest Price Target $0,43

In the last five quarters, Proteomics International Laboratories Ltd’s Price Target has fallen from $3,85 to $0,99 - a -74,29% decrease. One analysts predict that Proteomics International Laboratories Ltd’s share price will increase in the coming year, reaching $0,43. This would represent an increase of 53,57%.

Top growth stocks in the health care sector (5Y.)

What does Proteomics International Laboratories Ltd do?

Proteomics International Laboratories Ltd focuses on providing innovative solutions through research and development in the field of proteomics. The company is dedicated to advancing the understanding of proteins and their functions, which are crucial for disease diagnosis, treatment, and prevention. Business Segments The company operates as a single segment, focusing on the convergence of its revenues and the expansive research and development activities. This structure allows for streamlined...

Business Segments

The company operates as a single segment, focusing on the convergence of its revenues and the expansive research and development activities. This structure allows for streamlined decision-making and an integrated approach to monitoring its operational performance. The company provides performance evaluations that include actual vs. budget items.

The operations encompass various activities from R&D support to marketing efforts required for bringing innovative products to market. The revenue generation process involves obtaining regulatory approvals, ensuring manufacturing capabilities, and efficient marketing to potential clients. The company’s focus on research and development reaches out to various stakeholders, emphasizing collaboration with industry giants, healthcare facilities, and academic institutions to optimize the translational practices in proteomics.

By centralizing operations in this single segment, the company can address the challenges and risks associated with development timelines, resource allocation, and regulatory compliance. The unified approach to managing the company’s various activities allows it to respond effectively to market demands while simultaneously maximizing efficiency.

Business Strategy

The company’s business strategy centers on maximizing shareholder value while ensuring the sustainable development of innovative products and services. The leadership is focused on both organic growth through internal innovation and strategic partnerships. The company aims to invest in research and development that outpaces competitors and meets emerging healthcare needs. By fostering a culture of innovation and creativity, the company encourages its teams to pursue groundbreaking research that can lead to successful product commercialization.

Additionally, marketing and distribution capabilities are crucial to translating research discoveries into market-ready products. The company emphasizes the importance of compliance with all legal and regulatory standards, understanding that success in commercialization hinges on the ability to navigate the complexities of pharmaceutical regulations. The strategy employs meticulous planning to ensure that logistical, regulatory, and marketing aspects are aligned effectively to support product launch.

The company acknowledges that research and development processes are inherently risky and time-consuming, often spanning a decade or more. As such, it operates with a robust risk management framework that allows for adaptive strategy adjustments at each phase of product development. By identifying and mitigating potential setbacks early, the company can maintain momentum towards successful product offerings.

Products and Services

The company is engaged in the development and provision of sophisticated services and products focused on proteomics. These offerings primarily include research and development services, diagnostics solutions, and consulting services designed to assist partners in navigating the complexities associated with proteomic technologies.

The company specializes in bioinformatics, a crucial area that leverages computational techniques to analyze biological data, enabling accurate insights into disease mechanisms and protein functions. The innovative diagnostics services help healthcare professionals in identifying and monitoring diseases based on proteomic data.

Geographical Markets Served

The company primarily operates within markets across Australia and the United States, focusing on strategic collaboration with industry and academic partners.

Customers

The company serves a diverse customer base encompassing healthcare providers, academic institutions, and research organizations. While specific customer names are not disclosed, the scope includes major medical institutions and pharmaceutical companies that rely on proteomic insights for product development and clinical applications.

The customer base spans various categories, indicating broad interest and applicability of the company's research and diagnostic services. The company’s outreach and its integration into existing healthcare ecosystems.

Sales and Marketing

The company employs a mixed marketing strategy that combines direct engagement with potential clients through presentations, discussions, and participation in relevant industry conferences. Collaborations with renowned research institutions also enhance networking and establish trust within the industry.

Distribution channels extend into partnerships with third-party organizations, thus leveraging established networks to heighten market reach and product exposure. This comprehensive marketing framework allows for efficient engagement with end users while ensuring compliance with industry regulations.

History

Proteomics International Laboratories Ltd was founded in 2001. The company was incorporated in 2014.

New support ticket

Explore

Proteomics International Laboratories Ltd Stock Value

Proteomics International Laboratories Ltd Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Proteomics International Laboratories Ltd do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Proteomics International Laboratories Ltd Stock Value

Proteomics International Laboratories Ltd Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Proteomics International Laboratories Ltd do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.